Coronavirus outbreak: Pfizer-BioNTech vaccine cleared for human tests

The trial, only the fourth worldwide of a vaccine targeting the virus, will be initially conducted on 200 healthy people aged 18 to 55 years in first stage

Pfizer and BioNTech secured approval for Germany’s first human clinical trials of a possible coronavirus vaccine, entering a global race to develop a defense against the pandemic. The trial, only the fourth worldwide of a vaccine targeting the virus, will be initially conducted on 200 healthy people aged 18 to 55 years in the first stage, and on additional high-risk candidates in the second stage, according to a statement on Wednesday.
 

The companies said they expect to win approval for testing in the US shortly.
 

“It’s a good sign that the development of vaccines in Germany is at a stage